Should You Buy This Volatile Mid Cap Stock-BRKR

Acrobull Canada Advisory Inc.

February 11			2025
Name	Ticker	Sector/Industry		Market Cap	Risk Factor
Bruker Corporation	BRKR-NASDAQ	Technology		$7.678 Billion	Medium

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.

Recent Highlights

The company has recently announced the launch of the LUMOS™ II ILIM , a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution.

The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both transmission and reflection mode. With a very large field of view and complete automation, it allows for the rapid determination of chemical complexity in biological tissues.

First Quarter 2024 Financial Highlights

Bruker’s revenues for the first quarter 2024 were $721.7 million, an increase of 5.3% compared to $685.3 million in Q1 2023. In the first quarter of 2024, revenues increased 1.6% organically yoy. Growth from acquisitions was 3.8%, while foreign currency translation had a negative effect of 0.1%.

First quarter 2024 Bruker Scientific Instruments (BSI) segment revenues of $651.1 million increased 3.9% yoy, with organic revenue flat. First quarter 2024 Bruker Energy & Supercon Technologies (BEST) segment revenues of $73.1 million increased 17.5% yoy, with organic revenue growth, net of intercompany eliminations, of 18.9%.

First quarter 2024 GAAP operating income was $64.8 million, compared to $122.7 million in Q1 2023. NonGAAP operating income was $100.7 million in the first quarter of 2024, compared to $139.4 million in Q1 2023. Bruker’s first quarter 2024 non-GAAP operating margin was 14.0%, compared to 20.3% in Q1 2023.

First quarter 2024 GAAP diluted earnings per share (EPS) were $0.35, compared to $0.52 in Q1 2023. First quarter 2024 non-GAAP diluted EPS were $0.53, compared to $0.64 in Q1 2023.

Stock Observation- The company is set to report the financial results today hence it is expected to be volatile however it is expected to report strong financial results. Customers looking for volatile stock high risk appetite may choose to invest. The RSI level for the stock is at 34 which shows oversold conditions.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull Canada Advisory Inc. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrobull Canada Advisory Inc. only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrobull Canada Advisory Inc. would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull Canada Advisory Inc. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull Canada Advisory Inc. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$50.64 USD
Acrobull Recommendation	Buy
Target Price	Target $57.25 USD
RSI Level	14 Day RSI 34
Total Shares Outstanding	151.6 Million
Shares held by Insiders Risk Factor Stop Loss	31.92% Medium 5%